The limited number of systemic antifungals and the emergence of azole-resistant Candida 27 species constitute a growing challenge to human medicine. Combinatorial drug therapy represents 28 an appealing approach to enhance the activity of, or restore the susceptibility to current antifungals. 29 Here, we evaluated the fluconazole chemosensitization activity of the Pharmakon 1600 drug 30 library against azole-resistant Candida albicans. We identified 33 non-antifungal drugs that were 31 able to restore susceptibility to fluconazole in an azole-resistant C. albicans. Structural 32 investigation of identified hits revealed phenylpentanol scaffold as a valuable pharmacophore for 33 re-sensitizing azole-resistant Candida species to the effect of current azole antifungal drugs. All 34 phenylpentanol derivatives displayed potent fluconazole chemosensitizing activities (ΣFICI 0.13-35 0.28) and were able to reduce fluconazole's MIC by 15-31 fold against the tested strain.
narrow-spectrum synergistic relationship, as only 9 out of 18 of the tested Candida strains (50%) 138 responded to the pitavastatin-itraconazole combination ( Supplementary Table- 3).
139
Effect of the pitavastatin-fluconazole combination on the growth kinetics of Candida species. 140 The checkerboard microdilution assays revealed a significant synergistic relationship between 141 pitavastatin and fluconazole that was effective against C. albicans, C. glabrata, and C. auris. To phenylpentanol on the efflux activity of C. albicans strains with known mechanisms of efflux 161 hyperactivity (SC-TAC1 R34A , TWO7243, SC-MRR1 R34A , and TWO7241). Using the Nile Red 162 efflux assay and flow cytometric analysis, we studied the effect of pitavastatin on Candida's efflux 163 activity against two major membrane exporters, the ATP-binding cassette (ABC) and the major 164 facilitator superfamily (MFS) membrane transporters. As shown in Figure- 
168
The effect of pitavastatin on Candida's efflux activities was further confirmed using flow 169 cytometry. C. albicans SC-TAC1 R34A exhibited a significant increase in Nile Red fluorescence 170 intensity when exposed to pitavastatin (at 0.25 × MIC), compared to the glucose treated control 171 ( Figure 5a ). The pitavastatin effect on Nile Red efflux observed in strain SC-TAC1 R34A was 172 equivalent to the effect of 2-deoxyglucose, which interferes with Candida's efflux activities by 173 hindering its ability to produce ATP. However, pitavastatin did not affect the Nile Red efflux 174 activity of C. albicans SC-MRR1 R34A and the Nile red fluorescence intensity was similar to the 175 glucose treated control (Figure 5b ), which is in agreement with our previous observations. In order to explore new co-drugs capable of sensitizing resistant strains of Candida to the 185 effect of azoles, we investigated the azole chemosensitizing activity of 1600 drugs and clinical 186 molecules present in the Pharmakon drug library. Although the initial screening revealed a set of 187 structurally diverse molecules, we observed the phenylpentanol scaffold was present in nine 188 positive hits that belong to seven different pharmacological categories. To confirm that the 189 phenylpentanol scaffold is vital for the azole chemosensitizing activity observed in these hits, we 190 evaluated the activity of sex additional phenylpentanol derivatives that were not present in the The azole chemosensitizing activity of statins has been attributed to their ability to interfere 223 with the fungal ergosterol biosynthesis, however, this mechanism does not explain statins' 
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Effect of the pitavastatin-fluconazole combination on reducing the fungal burden in
244
In conclusion, we were able to identify phenylpentanol as a common core structure present 245 in the most potent azole chemosensitizing agents identified in our screening. The pitavastatin-246 fluconazole combination exhibited broad-spectrum synergistic interactions against clinically-247 relevant Candida species. Remarkably, pitavastatin was able to restore the susceptibility of the 248 multidrug-resistant C. auris isolates to the antifungal activities of itraconazole and voriconazole.
249
The azole chemosensitization activity displayed by pitavastatin is attributed, at least in part, to its 250 ability to interfere with Candida's efflux machinery. Furthermore, the efflux inhibitory activity 
Screening of Pharmakon library and structurally-related compounds.
275
The Pharmakon 1600 drug library was screened against the azole-resistant C. albicans NR-29448. 276 An overnight culture of C. albicans NR-29448 was diluted to approximately 0.5 -2.5 × 10 3 cells/ml and C. auris 385 demonstrated prominent ability to form robust adherent biofilms. As such, these 299 strains were used to study the antibiofilm activity of the pitavastatin-fluconazole combination. The 300 microtiter biofilm formation assay using crystal violet was used, as previously described [26] . 301 Briefly, overnight cultures of the tested Candida strains, grown in YPD broth, were diluted in RPMI 302 1640 medium to approximately 1 × 10 5 CFU/ml. Then 100 µl aliquots of each suspension were 303 transferred to wells in 96-well plates. Aliquots of two-fold serial dilutions of pitavastatin, at 304 concentrations ranging from 64 to 0.25 µg/ml, were transferred to the 96-well biofilm assay plates 305 and plates were incubated at 35°C for 24 h. Pitavastatin was tested either individually or in 306 combination with fluconazole (2 µg/ml). The adherent biofilms were then rinsed twice with 307 phosphate-buffered saline (PBS) and left to dry at room temperature. Air-dried biofilms were 308 stained with crystal violet (0.1%). Stained biofilms were rinsed thrice with PBS and then air dried.
309
The resultant biofilm biomasses were quantified by dissolving the crystal violet-stained biofilms in 310 absolute ethanol before recording absorbance values (OD595).
311
Nile red glucose-induced efflux assay and flow cytometry. Nile Red efflux assays were 312 performed following a previously reported protocol [30, 47, 48] . Nile red fluorescence intensity 313 was measured at an excitation wavelength of 485 and an emission wavelength of 528 using the MYA-2950, and c) C. auris 390 were diluted to 0.5-2.5 × 10 3 CFU/ml in RPMI 1640 medium.
526
Cells were treated with pitavastatin, fluconazole (FLC), or a combination of the two drugs at the 527 indicated concentrations. Cells were incubated at 35 o C for 48 h, and OD595 values were measured 528 at different time points (0, 6, 12, 18, 24, 36 and 48 h) . 
